Insight

Earle Burgess: For men with metastatic prostate cancer who are taking abiraterone and prednisone

Photo from Earle Burgess/LinkedIn

Aug 13, 2024, 19:23

Earle Burgess: For men with metastatic prostate cancer who are taking abiraterone and prednisone

Earle Burgess, Atrium Health Levine Cancer Institute, shared a post on LinkedIn:

“For men with metastatic prostate cancer who are taking abiraterone and prednisone:

When your PSA level starts to rise, that indicates the emergence of growing, resistant cancer cells.Did you know that switching prednisone to dexamethasone (but continuing abiraterone) might lead to another PSA response.(This is only appropriate for men who do not have cancer-related symptoms when the PSA starts to rise.)By making this switch, roughly 30% of men will see a PSA response of 50% or greater.For men who respond to this strategy, it might delay the time until your doctor needs to make a more significant change in your treatment plan.Ask your doctor about this if you think it may be appropriate for you.”

Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

Authors: Zhenyu Yang, Yuchao Ni, Diwei Zhao , Yijun Zhang , Jun Wang, Lijuan Jiang, Dong Chen , Zhiming Wu, Yanjun Wang , Liru He , Yanxia Shi, Fangjian Zhou , Hao Zeng, and, Yonghong Li.

Earle Burgess: For men with metastatic prostate cancer who are taking abiraterone and prednisone

Source: Earle Burgess/LinkedIn

abiraterone Atrium Health Levine Cancer Institute cancer Diwei Zhao Earle Burgess Fangjian Zhou Hao Zeng metastatic prostate cancer OncoDaily Oncology prednisone PSA Yonghong Li Yuchao Ni Zhenyu Yang

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage